-
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights (opens in a new tab)
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data…
-
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET (opens in a new tab)
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 (opens in a new tab)
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T…
-
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress (opens in a new tab)
MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants (opens in a new tab)
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants (opens in a new tab)
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (opens in a new tab)
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes (opens in a new tab)
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the…
-
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights (opens in a new tab)
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by…
-
SAB BIO to Participate in Upcoming Investor Conferences (opens in a new tab)
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO to Participate in Upcoming Investor Conferences (opens in a new tab)
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
-
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director (opens in a new tab)
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB…